Analysts Issue Forecasts for AKRO FY2029 Earnings

Akero Therapeutics, Inc. (NASDAQ:AKRO) – Stock analysts at HC Wainwright issued their FY2029 EPS estimates for Akero Therapeutics in a research report issued on Monday, January 27th. HC Wainwright analyst E. Arce forecasts that the company will post earnings per share of $5.58 for the year. HC Wainwright currently has a “Buy” rating and a $72.00 target price on the stock. The consensus estimate for Akero Therapeutics’ current full-year earnings is ($3.96) per share.

Akero Therapeutics (NASDAQ:AKRO) last posted its quarterly earnings data on Friday, November 8th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.15).

Other research analysts have also recently issued reports about the stock. Morgan Stanley raised their target price on shares of Akero Therapeutics from $46.00 to $96.00 and gave the stock an “overweight” rating in a report on Tuesday. Citigroup raised their price objective on shares of Akero Therapeutics from $65.00 to $80.00 and gave the stock a “buy” rating in a research note on Tuesday. Bank of America upgraded shares of Akero Therapeutics from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $35.00 to $63.00 in a research report on Thursday. Finally, Canaccord Genuity Group increased their target price on Akero Therapeutics from $56.00 to $73.00 and gave the company a “buy” rating in a report on Tuesday. Nine research analysts have rated the stock with a buy rating, According to MarketBeat.com, Akero Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $66.29.

Akero Therapeutics Stock Up 2.5 %

Shares of Akero Therapeutics stock opened at $55.36 on Wednesday. The stock’s fifty day moving average is $29.78 and its 200-day moving average is $28.69. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $3.86 billion, a PE ratio of -14.76 and a beta of -0.19. Akero Therapeutics has a 12-month low of $15.32 and a 12-month high of $58.40.

Insiders Place Their Bets

In other news, CEO Andrew Cheng sold 30,000 shares of the firm’s stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $54.90, for a total transaction of $1,647,000.00. Following the completion of the sale, the chief executive officer now directly owns 716,062 shares of the company’s stock, valued at $39,311,803.80. This trade represents a 4.02 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Timothy Rolph sold 31,250 shares of the business’s stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $55.77, for a total value of $1,742,812.50. Following the completion of the sale, the insider now directly owns 170,237 shares of the company’s stock, valued at approximately $9,494,117.49. The trade was a 15.51 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 149,303 shares of company stock worth $6,206,412 in the last quarter. 7.94% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Wellington Management Group LLP lifted its position in Akero Therapeutics by 54.4% during the 3rd quarter. Wellington Management Group LLP now owns 7,896,632 shares of the company’s stock worth $226,554,000 after acquiring an additional 2,782,029 shares during the last quarter. Janus Henderson Group PLC lifted its position in Akero Therapeutics by 2.9% in the third quarter. Janus Henderson Group PLC now owns 7,077,478 shares of the company’s stock worth $203,053,000 after purchasing an additional 201,225 shares during the period. RTW Investments LP increased its holdings in Akero Therapeutics by 9.0% in the 3rd quarter. RTW Investments LP now owns 5,919,435 shares of the company’s stock valued at $169,829,000 after buying an additional 487,450 shares during the period. Point72 Asset Management L.P. acquired a new position in shares of Akero Therapeutics in the 3rd quarter valued at $37,392,000. Finally, SG Americas Securities LLC lifted its holdings in shares of Akero Therapeutics by 4,022.1% during the 4th quarter. SG Americas Securities LLC now owns 597,993 shares of the company’s stock worth $16,636,000 after acquiring an additional 583,486 shares during the period.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.